Charles Zhu Analyst PerformanceManaging Director, Senior Research Analyst at Lifesci CapitalCharles Zhu is a stock analyst at Lifesci Capital in the medical sector, covering 3 publicly traded companies. Over the past year, Charles Zhu has issued 4 stock ratings, including strong buy, buy, and hold recommendations. While full access to Charles Zhu's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Charles Zhu's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings4 Last 0 YearsBuy Recommendations50.00% 2 Buy RatingsCompanies Covered3 Unique Companies Ratings Distribution4RatingsDistribution of strong buy, buy, hold, and sell ratings by Charles Zhu.RatingPercentageCount Strong Buy25.0%1 ratings Buy25.0%1 ratings Hold50.0%2 ratings Sell0.0%0 ratingsOut of 4 total stock ratings issued by Charles Zhu at Lifesci Capital, the majority (50.0%) have been Hold recommendations, followed by 25.0% Strong Buy and 25.0% Buy.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ3 companiesCharles Zhu, an analyst at Lifesci Capital, currently covers 3 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical3 companies100.0%Charles Zhu of Lifesci Capital specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE2 companies66.7%MED - DRUGS1 company33.3% About Charles ZhuCharles Zhu is a Senior Research Analyst at LifeSci Capital. Prior to joining the firm in 2024, Charles was a Director and Senior Biotech Analyst at Guggenheim Securities, LLC, where he worked for over 5 years covering small- and mid-cap oncology stocks. Prior to Guggenheim, he was a Consultant at The Dedham Group, LLC, where he specialized in pharmaceutical drug pricing and market access across multiple therapeutic areas including oncology, inflammation, and neurology. Charles holds a PhD in Biomedical Engineering from Rutgers University, where his dissertation focused on Actinium-225 as a cancer therapeutic, as well as BS and MEng degrees from Cornell University. Charles holds the Series 7, 86, and 87.Follow on LinkedIn Charles Zhu's Ratings History at Lifesci Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsTNGXTango Therapeutics10/24/2025Boost Price Target$7.53$12.00Buy$0.0000.00% ROIMRUSMerus9/30/2025Reiterated Rating$93.67$97.00Market Perform$0.0000.00% ROIMRUSMerus9/29/2025Downgrade$94.15Hold$0.0000.00% ROICBIOCrescent Biopharma6/18/2025Upgrade$13.27$22.00Strong-Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
